KRAS

Biomarkers

KRAS is involved in the following curated biomarkers.

Name	Biomarker type	Propositions	Statements
KRAS p.G12C	Somatic Variant	4	6
KRAS p.G12V	Somatic Variant	1	1
Wild type KRAS	Wild type	13	15

Therapeutic response

Precision oncology relationships for therapeutic response involving this gene.

Organization(s)	Biomarker(s)	Cancer type	Therapy(ies)
EMA (1) FDA (1)	KRAS p.G12C	Non-Small Cell Lung Cancer	Adagrasib
EMA (1) FDA (1)	KRAS p.G12C	Non-Small Cell Lung Cancer	Sotorasib
FDA (1)	KRAS p.G12C	Colorectal Adenocarcinoma	Adagrasib, Cetuximab
FDA (1)	KRAS p.G12C	Low-Grade Serous Ovarian Cancer	Avutometinib, Defactinib
FDA (1)	KRAS p.G12V	Low-Grade Serous Ovarian Cancer	Avutometinib, Defactinib
FDA (1)	EGFR positive, Wild type KRAS	Colorectal Adenocarcinoma	Cetuximab, Fluorouracil, Irinotecan
FDA (1)	EGFR positive, Wild type KRAS	Colorectal Adenocarcinoma	Cetuximab, Irinotecan
FDA (1)	EGFR positive, Wild type KRAS	Colorectal Adenocarcinoma	Cetuximab
FDA (1)	Wild type HRAS, Wild type KRAS	Colorectal Adenocarcinoma	Fluorouracil, Oxaliplatin, Panitumumab
FDA (1)	Wild type HRAS, Wild type KRAS	Colorectal Adenocarcinoma	Panitumumab
EMA (1)	EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Cetuximab
EMA (1)	EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Cetuximab, Irinotecan
EMA (1)	EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Cetuximab, Fluorouracil, Oxaliplatin
EMA (1)	Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Fluorouracil, Oxaliplatin, Panitumumab
EMA (2)	Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Fluorouracil, Irinotecan, Panitumumab
EMA (1) HSE (1)	Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Panitumumab
HSE (1)	Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Cetuximab, Fluorouracil, Irinotecan
FDA (1)	HER2-positive, Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Trastuzumab, Tucatinib